ClinicalTrials.gg
CompletedNCT06221826Updated Apr 27, 2025Results posted

MEXIDOL® in the Rehabilitation Treatment of Patients With Acute Cerebral Failure

A Phase 4 interventional study of Mexidol in Ischemic Stroke, Acute, sponsored by Pharmasoft. Completed at 1 site in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Pharmasoft · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Apr 2023, registered Jan 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Ischemic Stroke with a site in Russian Federation — 6 open to participants now, 6 under way, none of them phase 3. Ischemic Stroke · Russian Federation.

Enrollment
12th of 19
60 · median 120
Started
2023
with 1 other
Phase 4
3 of 28
1 open now
Registered
23rd of 28
by date
Lead sponsor
2 of 28
Pharmasoft

Among the 28 studies in Ischemic Stroke with a site in Russian Federation, this one is the 12th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2023, is one of 3 in phase 4, and was the 23rd registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

6 of the 28 studies in Ischemic Stroke with a site in Russian Federation are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Ischemic Stroke with a site in Russian Federation, or all of them as a file.
02

Study summary

The use of metabolic modulators creates prospects for increasing the efficiency of the rehabilitation treatment of patients with acute cerebral failure

Read the detailed description

Modern neurorehabilitation is a set of basic and adjuvant treatment methods that provide a modulating effect on the neurorestoration process. The range of basic rehabilitation practices includes kinesiotherapy, occupational therapy, speech therapy, and neuropsychology. Adjuvant methods include physiotherapeutic and medicinal methods. For this study, the investigators chose MEXIDOL® as an adjuvant metabolic medicine, which has the ability to modulate receptor complexes of brain membranes, in particular benzodiazepine, GABA, acetylcholine, enhancing their ability to bind to specific ligands. This pharmacodynamic feature of the drug can have a positive effect on the psycho-emotional state of patients, which in turn will increase motivation and, consequently, the success of the rehabilitation process

03

Conditions studied

  • Ischemic Stroke, Acute

Keywords

  • Ischemic Stroke
  • Acute Stroke
  • Cerebral stroke
  • Traumatic Brain Injury
  • Acute Cerebrovascular Accident
  • ACVA
  • Acute cerebral failure
  • Neuroprotection
  • Mexidol
  • Ethylmethylhydroxypyridine Succinate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Acute Ischemic Stroke
  • (MoCA) test >15; ≤22

Exclusion criteria

Exclusion Criteria:

  • Under 18 years old
  • Epilepsy
  • Pregnancy
  • Acute failure of one or more organ systems
  • Purulent-inflammatory disease of any localization
  • Participating in any other clinical trial
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Main (Mexidol and standard treatment)

    Mexidol IV 500 mg for 10 days, then Mexidol FORTE 250 orally 250 mg 1 tablet 3 times a day for 8 weeks; and standard treatment

    Drug: Mexidol

  • No intervention
    Control

    Standard treatment: basic practices of kinesitherapy, occupational therapy, speech therapy, clinical psychology, supplemented by adjuvant procedures of electrotherapy and rehabilitation environment therapy. The patient's rehabilitation load was at least 3 hours a day for 12 days

Interventions

  • Neurocytoprotector

    Also known as: Ethylmethylhydroxypyridine Succinate

06

What researchers measure

Primary outcomes

  1. Аssessment of Attentiveness and Performance

    Schulte test \[work efficiency\]. Test methodology: the subject is successively shown 5 tables (5x5), in the cells of which numbers (from 1 to 25) are randomly located. It is required to show and name all the numbers in ascending order (from 1 to 25). The time spent on each table separately is recorded. Depending on the objectives, the excess of the standard (40-50 sec) time spent on each table and the dynamics of time indicators, or the average or total result of the examination for all five tables, are analyzed \[test time: min value 30.0 sec, max value N/A; higher scores mean a worse outcome\].

    Time frame: Assessed before starting therapy (Day 1), at the end of the parenteral therapy phase (Day 10) and at the end of the course of therapy (Day 66).

  2. Dynamics of Cognitive Status

    The Montreal Cognitive Assessment (MoCA test) \[31 point scale: min value 0, max value 30, higher scores mean a better outcome\]

    Time frame: Assessed at screening (Day 0), at the end of the parenteral therapy phase (Day 10) and at the end of the course of therapy (Day 66); Day 66 reported

  3. Severity of Depression

    The Beck Depression Inventory (BDI scale) \[64 point scale: min value 0, max value 63, higher scores mean a worse outcome\]

    Time frame: Assessed before starting therapy (Day 1), at the end of the parenteral therapy phase (Day 10), in the middle of the oral therapy phase (Day 38) and at the end of the course of therapy (Day 66); Day 66 reported

  4. Reduction in Anxiety

    The Hospital Anxiety and Depression Scale (HADS) \[22 point scale: min value 0, max value 21, higher scores mean a worse outcome\]

    Time frame: Assessed before starting therapy (Day 1), at the end of the parenteral therapy phase (Day 10), in the middle of the oral therapy phase (Day 38) and at the end of the course of therapy (Day 66); Day 66 reported

  5. Severity of Post Intensive Care Syndrome

    The Post Intensive Care Syndrome (PICS) score \[21 point scale: min value 0, max value 10 with 0,5 point scale division, higher scores mean a worse outcome\]

    Time frame: Assessed before starting therapy (Day 1), at the end of the parenteral therapy phase (Day 10), in the middle of the oral therapy phase (Day 38) and at the end of the course of therapy (Day 66); Day 66 reported

  6. Dynamics of Level of Mobility

    The Rivermead index \[16 point scale: min value 0, max value 15, higher scores mean a better outcome\]

    Time frame: Assessed before starting therapy (Day 1), at the end of the parenteral therapy phase (Day 10), in the middle of the oral therapy phase (Day 38) and at the end of the course of therapy (Day 66); Day 66 reported

  7. Dynamics of the Level of Life

    The Rehabilitation Routing Scale (RRS) \[7 point scale: min value 0, max value 6, higher scores mean a worse outcome\]

    Time frame: Assessed at screening (Day 0), at the end of the parenteral therapy phase (Day 10), in the middle of the oral therapy phase (Day 38) and at the end of the course of therapy (Day 66); Day 66 reported

  8. Severity and Dynamics of Muscle Strength

    The Muscle Strength Quantitative Rating (MRC) Scale \[6 point scale: min value 0, max value 5, higher scores mean a better outcome\]

    Time frame: Assessed before starting therapy (Day 1), at the end of the parenteral therapy phase (Day 10), in the middle of the oral therapy phase (Day 38) and at the end of the course of therapy (Day 66); Day 66 reported

  9. Systolic Cerebral Blood Flow Velocity (Vs) Using Transcranial Doppler (TCD) at Key Time Points

    Systolic cerebral blood flow velocity (Vs) was measured in сm/sec using transcranial Doppler ultrasonography (TCD). Measurements were taken for each participant at five key time points: (1) before the first Mexidol infusion ("Before infusion"), (2) at the start of the infusion, (3) at the start of the Schulte test, (4) at the end of the Schulte test, and (5) at the end of the infusion. \[Normal values: min 35 сm/sec, max 95 сm/sec\]

    Time frame: The TCDG parameters registrated before infusion, at the start of the infusion, at the start of the Schulte test, at the end of the Schulte test, at the end of the infusion.

  10. Overshoot Coefficient (OC) of Systolic Cerebral Blood Flow Velocity (TCD) at Key Time Points

    The Overshoot Coefficient (OC) is a ratio reflecting the change in systolic cerebral blood flow velocity before and after specific stimuli. It was calculated based on transcranial Doppler measurements at five key time points: (1) before the first Mexidol infusion ("Before infusion"), (2) at the start of the infusion, (3) at the start of the Schulte test, (4) at the end of the Schulte test, and (5) at the end of the infusion. \[It's calculated by the formula OC=(Vo-Vs)/Vs, the norm is not less than 1.12\]

    Time frame: The TCDG parameters registrated before infusion, at the start of the infusion, at the start of the Schulte test, at the end of the Schulte test, at the end of the infusion.

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Registration of adverse events related to Mexidol and significant differences in vital signs between groups

    Time frame: Throughout the study [From Day 1 up to Day 66]

07

Results

Posted Apr 27, 2025

Participant flow

Participant flow — Overall Study
MilestoneMain (Mexidol and Standard Treatment)Control
Started3030
Completed3030
Not completed00

Outcome measures

PrimaryАssessment of Attentiveness and Performance

Schulte test \[work efficiency\]. Test methodology: the subject is successively shown 5 tables (5x5), in the cells of which numbers (from 1 to 25) are randomly located. It is required to show and name all the numbers in ascending order (from 1 to 25). The time spent on each table separately is recorded. Depending on the objectives, the excess of the standard (40-50 sec) time spent on each table and the dynamics of time indicators, or the average or total result of the examination for all five tables, are analyzed \[test time: min value 30.0 sec, max value N/A; higher scores mean a worse outcome\].

Time frame:
Assessed before starting therapy (Day 1), at the end of the parenteral therapy phase (Day 10) and at the end of the course of therapy (Day 66).
Reported as:
Median · seconds
Аssessment of Attentiveness and Performance
secondsMain (Mexidol and Standard Treatment)Control
Day 194.9 (69.35 to 114.95)71.2 (65.15 to 87.9)
Day 1075 (60.9 to 95.7)68.15 (62.15 to 88.65)
Day 6671.7 (56.65 to 102.3)63 (55.73 to 82.95)
PrimaryDynamics of Cognitive Status

The Montreal Cognitive Assessment (MoCA test) \[31 point scale: min value 0, max value 30, higher scores mean a better outcome\]

Time frame:
Assessed at screening (Day 0), at the end of the parenteral therapy phase (Day 10) and at the end of the course of therapy (Day 66); Day 66 reported
Reported as:
Mean · score on a scale
Dynamics of Cognitive Status
score on a scaleMain (Mexidol and Standard Treatment)Control
Dynamics of Cognitive Status23.8 ± 2.622.9 ± 3.0
PrimarySeverity of Depression

The Beck Depression Inventory (BDI scale) \[64 point scale: min value 0, max value 63, higher scores mean a worse outcome\]

Time frame:
Assessed before starting therapy (Day 1), at the end of the parenteral therapy phase (Day 10), in the middle of the oral therapy phase (Day 38) and at the end of the course of therapy (Day 66); Day 66 reported
Reported as:
Mean · score on a scale
Severity of Depression
score on a scaleMain (Mexidol and Standard Treatment)Control
Severity of Depression7.5 ± 4.511.4 ± 5.6
PrimaryReduction in Anxiety

The Hospital Anxiety and Depression Scale (HADS) \[22 point scale: min value 0, max value 21, higher scores mean a worse outcome\]

Time frame:
Assessed before starting therapy (Day 1), at the end of the parenteral therapy phase (Day 10), in the middle of the oral therapy phase (Day 38) and at the end of the course of therapy (Day 66); Day 66 reported
Reported as:
Mean · score on a scale
Reduction in Anxiety
score on a scaleMain (Mexidol and Standard Treatment)Control
Reduction in Anxiety2.6 ± 2.44.4 ± 2.4
PrimarySeverity of Post Intensive Care Syndrome

The Post Intensive Care Syndrome (PICS) score \[21 point scale: min value 0, max value 10 with 0,5 point scale division, higher scores mean a worse outcome\]

Time frame:
Assessed before starting therapy (Day 1), at the end of the parenteral therapy phase (Day 10), in the middle of the oral therapy phase (Day 38) and at the end of the course of therapy (Day 66); Day 66 reported
Reported as:
Mean · score on a scale
Severity of Post Intensive Care Syndrome
score on a scaleMain (Mexidol and Standard Treatment)Control
Severity of Post Intensive Care Syndrome0.02 ± 0.090.3 ± 0.6
PrimaryDynamics of Level of Mobility

The Rivermead index \[16 point scale: min value 0, max value 15, higher scores mean a better outcome\]

Time frame:
Assessed before starting therapy (Day 1), at the end of the parenteral therapy phase (Day 10), in the middle of the oral therapy phase (Day 38) and at the end of the course of therapy (Day 66); Day 66 reported
Reported as:
Mean · score on a scale
Dynamics of Level of Mobility
score on a scaleMain (Mexidol and Standard Treatment)Control
Dynamics of Level of Mobility10.3 ± 2.88.0 ± 2.8
PrimaryDynamics of the Level of Life

The Rehabilitation Routing Scale (RRS) \[7 point scale: min value 0, max value 6, higher scores mean a worse outcome\]

Time frame:
Assessed at screening (Day 0), at the end of the parenteral therapy phase (Day 10), in the middle of the oral therapy phase (Day 38) and at the end of the course of therapy (Day 66); Day 66 reported
Reported as:
Mean · score on a scale
Dynamics of the Level of Life
score on a scaleMain (Mexidol and Standard Treatment)Control
Dynamics of the Level of Life2.9 ± 0.73.3 ± 0.6
PrimarySeverity and Dynamics of Muscle Strength

The Muscle Strength Quantitative Rating (MRC) Scale \[6 point scale: min value 0, max value 5, higher scores mean a better outcome\]

Time frame:
Assessed before starting therapy (Day 1), at the end of the parenteral therapy phase (Day 10), in the middle of the oral therapy phase (Day 38) and at the end of the course of therapy (Day 66); Day 66 reported
Reported as:
Mean · score on a scale
Severity and Dynamics of Muscle Strength
score on a scaleMain (Mexidol and Standard Treatment)Control
Severity and Dynamics of Muscle Strength3.3 ± 5.12.1 ± 2.2
PrimarySystolic Cerebral Blood Flow Velocity (Vs) Using Transcranial Doppler (TCD) at Key Time Points

Systolic cerebral blood flow velocity (Vs) was measured in сm/sec using transcranial Doppler ultrasonography (TCD). Measurements were taken for each participant at five key time points: (1) before the first Mexidol infusion ("Before infusion"), (2) at the start of the infusion, (3) at the start of the Schulte test, (4) at the end of the Schulte test, and (5) at the end of the infusion. \[Normal values: min 35 сm/sec, max 95 сm/sec\]

Time frame:
The TCDG parameters registrated before infusion, at the start of the infusion, at the start of the Schulte test, at the end of the Schulte test, at the end of the infusion.
Reported as:
Mean · сm/sec
Systolic Cerebral Blood Flow Velocity (Vs) Using Transcranial Doppler (TCD) at Key Time Points
сm/secMain (Mexidol and Standard Treatment)Control
Before infusion72.6 ± 18.4180.03 ± 33.49
Start of the infusion72.23 ± 17.6880.8 ± 33.09
Start of the Schulte test74.6 ± 18.7383.57 ± 34.3
End of the Schulte test76.83 ± 17.7680.87 ± 31.98
End of the infusion78.53 ± 17.7883.57 ± 32.29
PrimaryOvershoot Coefficient (OC) of Systolic Cerebral Blood Flow Velocity (TCD) at Key Time Points

The Overshoot Coefficient (OC) is a ratio reflecting the change in systolic cerebral blood flow velocity before and after specific stimuli. It was calculated based on transcranial Doppler measurements at five key time points: (1) before the first Mexidol infusion ("Before infusion"), (2) at the start of the infusion, (3) at the start of the Schulte test, (4) at the end of the Schulte test, and (5) at the end of the infusion. \[It's calculated by the formula OC=(Vo-Vs)/Vs, the norm is not less than 1.12\]

Time frame:
The TCDG parameters registrated before infusion, at the start of the infusion, at the start of the Schulte test, at the end of the Schulte test, at the end of the infusion.
Reported as:
Mean · ratio
Overshoot Coefficient (OC) of Systolic Cerebral Blood Flow Velocity (TCD) at Key Time Points
ratioMain (Mexidol and Standard Treatment)Control
Before infusion1.25 ± 0.051.27 ± 0.05
Start of the infusion1.26 ± 0.041.27 ± 0.04
Start of the Schulte test1.25 ± 0.051.27 ± 0.04
End of the Schulte test1.26 ± 0.051.27 ± 0.04
End of the infusion1.27 ± 0.051.28 ± 0.04
SecondaryIncidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

Registration of adverse events related to Mexidol and significant differences in vital signs between groups

Time frame:
Throughout the study [From Day 1 up to Day 66]
Reported as:
Number · Adverse events
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Adverse eventsMain (Mexidol and Standard Treatment)Control
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]00

Adverse events

Collected over Throughout the study [From Day 1 up to Day 66]. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Main (Mexidol and Standard Treatment)0/30 (0%)0/30 (0%)0/30 (0%)
Control0/30 (0%)0/30 (0%)0/30 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Main (Mexidol and Standard Treatment)ControlTotal
<=18 years000
Between 18 and 65 years25631
>=65 years52429
Age, Continuous
Age, Continuous(years)Main (Mexidol and Standard Treatment)ControlTotal
Mean63.9 ± 10.366.6 ± 9.465.3 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)Main (Mexidol and Standard Treatment)ControlTotal
Female131730
Male171330
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Main (Mexidol and Standard Treatment)ControlTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)Main (Mexidol and Standard Treatment)ControlTotal
Russia303060
Cognitive status [MoCA]
Cognitive status [MoCA](units on a scale)Main (Mexidol and Standard Treatment)ControlTotal
Mean19.1 ± 2.2619.6 ± 1.8319.35 ± 2.05
The Rehabilitation Routing Scale (RRS)
The Rehabilitation Routing Scale (RRS)(units on a scale)Main (Mexidol and Standard Treatment)ControlTotal
Mean3.9 ± 0.44.1 ± 0.54.0 ± 0.5
08

Study locations

1 site
  • Brain Institute Clinic
    Ekaterinburg, Sverdlovsk Region 623702, Russian Federation
09

References and documents

Publications

  • Belkin AA, Belkin VA, Vasilchenko IE, Pinchuk EA. [Results of a cohort single-center randomized study of the modulating effect of the drug Mexidol in the rehabilitation of patients who suffered acute cerebral insufficiency]. Zh Nevrol Psikhiatr Im S S Korsakova. 2024;124(4):108-117. doi: 10.17116/jnevro2024124041108. Russian. PubMed 38676685 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Sep 2023, 4 months.

Results were first posted in Apr 2025, 1 year 7 months after primary completion.

Of 85 phase 4 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 41. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2024
First posted
Jan 24, 2024
StartActual
Apr 17, 2023
Primary completionActual
Sep 12, 2023
CompletionActual
Sep 12, 2023
Results first posted
Apr 27, 2025
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06221826
Lead sponsor
Pharmasoft
Responsible party
Sponsor
First posted
Jan 24, 2024
Start date
Apr 17, 2023
Primary completion
Sep 12, 2023
Completion
Sep 12, 2023
Results posted
Apr 27, 2025
Last update
Apr 27, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emoxypine succinate

Start the discussion